Search

Oxaliplatin is a third-generation platinum complex, and has a broad spectrum of antitumor activity. Such platinum complexes with the DACH carrier ligand have recently received increasing attention since they show efficacy against cisplatin-resistant cell lines. As the foremost indication of antitumor activity of platinum drugs is the formation of adducts with genomic DNA, calf thymus DNA-oxaliplatin adducts were the major target in this study. Calf thymus DNA was incubated with oxaliplatin, resulting in the formation of a large number of platinum-DNA adducts. Treated DNA was digested into the dinucleotides with a combination of enzymes, namely, benzonase, alkaline phosphatase, and nuclease S1. Using a high-performance liquid chromatography, we carried out the separation of individual platinum-DNA adducts which were concurrently identified using electrospray ionization ion trap mass spectrometry (MS). Both 1,2-intrastrand and 1,2-interstrand cross-linked adducts were found; however, those of the intrastrand nature have a considerably higher abundance than those of the interstrand cross-links. Among them, d(GpG)-oxaliplatin was the most abundant bifuctional adduct. To a lesser extent, a few monofunctional adducts were detected as well. MS(n) experiments served to ascertain the detailed structures of oxaliplatin adducts of dinucleoside monophosphates and of dinucleotides.

Accumulating evidence suggests a critical role of intracellular glutathione in tumor cell resistance to alkylating agents. The present study provides evidence for the direct interaction between cis-diamminedichloroplatinum(II) (cisplatin) and glutathione (GSH) both in a cell-free system, as well as in L1210 murine leukemia cells. We have isolated the reaction product and identified it by a combination of high performance liquid chromatography and atomic absorption spectroscopy. Stoichiometric analysis showed a 2:1 molar ratio of GSH/cisplatin for the reaction. The molecular mass assessed by mass spectroscopy was 809 Da, corresponding to a GS-platinum chelate complex, bis-(glutathionato)-platinum. The GS-platinum complex was detected in L1210 leukemia cells incubated with 20 microM cisplatin. The intracellular content of the GS-platinum complex reached a maximal level after 12 h, corresponding to about 60% of the intracellular platinum content. Thus, formation of the GS-platinum complex is considered a significant part of the cellular metabolism of cisplatin. The GS-platinum was found to inhibit cell-free protein synthesis in a rabbit reticulocyte lysate system using both chloramphenicol acetyltransferase mRNA and poly(A) mRNA from HL-60 human promyelocytic leukemia cells (IC50 = 190 microM the GS-platinum complex). Elimination of the GS-platinum complex from tumor cells may represent an important mechanism which reduces the intracellular accumulation of the platinum complex. Using plasma membrane vesicles prepared from L1210 cells, the transport of the GS-platinum complex across the plasma membrane was found to be an ATP-dependent process (apparent Km values: 49 microM, ATP; 110 microM, GS-platinum complex). The ATP-dependent transport of the GS-platinum complex was inhibited by vanadate (IC50 = 35 microM) as well as by S-(2,4-dinitrophenyl)-glutathione, leukotriene C4, and GSSG, but not by doxorubicin, daunorubicin, or verapamil. The ATP-dependent glutathione S-conjugate export pump, "GS-X pump" (Ishikawa, T. (1992) Trends Biochem. Sci. 17, 463-468), is suggested to play a role in the elimination of the GS-platinum complex from tumor cells.